Cadian Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Cadian Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-100,665	Closed	-$2.09M	–	53
2016 Q4	$2.09M	Sell	100,665 -140,000	-58%	-$3.64M	0.11%	41
2016 Q3	$7.89M	Sell	240,665 -376,200	-61%	-$11.5M	0.42%	40
2016 Q2	$15.4M	Buy	616,865 +530,000	+610%	+$14.3M	0.85%	30
2016 Q1	$2.13M	Sell	86,865 -302,835	-78%	-$7.01M	0.14%	51
2015 Q4	$12.9M	Hold	389,700	–	–	0.46%	49
2015 Q3	$12.8M	Sell	389,700 -35,300	-8%	-$1.5M	0.46%	55
2015 Q2	$22.5M	Buy	425,000 +370,000	+673%	+$13.5M	0.66%	34
2015 Q1	$1.59M	Buy	+55,000	New	+$1.51M	0.04%	77
2014 Q4	–	Sell	-120,000	Closed	-$1.52M	–	107
2014 Q3	$1.52M	Buy	120,000 +20,000	+20%	+$302K	0.04%	79
2014 Q2	$2.01M	Buy	+100,000	New	+$1.41M	0.06%	73

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Cadian Capital Management's ALDR Position: Q1 2017 in Review

Cadian Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q1 2017, closing a stake of 100,665 shares — an estimated $2.09M sold.

Cadian Capital Management first reported a position in ALDR in Q2 2014 and held it in 10 quarters. The position peaked at $22.5M in Q2 2015. 142 funds tracked by Wall St. Rank hold ALDR as of Q1 2017.

Cadian Capital Management reported no remaining Alder Biopharmaceuticals position as of Q1 2017 after selling out during the quarter.
Cadian Capital Management sold 100,665 Alder Biopharmaceuticals shares in Q1 2017, an estimated $2.09M.
Cadian Capital Management first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 10 quarters.
Cadian Capital Management's Alder Biopharmaceuticals position peaked at $22.5M in Q2 2015.
142 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q1 2017.

Based on Cadian Capital Management's 13F filing for Q1 2017, filed 12 May 2017.